Abstract
Soluble CD83 (sCD83), a potent immunosuppressive agent, circulates at elevated levels in some chronic lymphocytic leukemia (CLL) patients. We report that CLL patients with elevated plasma sCD83 levels had significantly shorter (P=0.038) treatment free survival. Culture of CLL cells with solid phase CD83 mAb+IL-4 significantly increases sCD83 release (23-117-fold, P=0.013) and ligation of normal donor PBMC with solid phase CD83 mAb alone induces similar significant increases in sCD83 release (P=0.003). RT-PCR analysis detected the presence of a transcript for sCD83 in 2/3 CLL samples. These results suggest sCD83 release may play a regulatory role in CLL progression.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / pharmacology
-
Antigens, CD / blood*
-
Antigens, CD / immunology
-
CD83 Antigen
-
Chronic Disease
-
Disease-Free Survival
-
Female
-
Humans
-
Immunoglobulins / blood*
-
Immunoglobulins / immunology
-
Interleukin-4 / immunology
-
Interleukin-4 / pharmacology
-
Leukemia, Lymphoid / blood*
-
Leukemia, Lymphoid / drug therapy
-
Leukemia, Lymphoid / immunology
-
Leukemia, Lymphoid / mortality
-
Male
-
Membrane Glycoproteins / blood*
-
Membrane Glycoproteins / immunology
-
Middle Aged
-
Neoplasm Proteins / blood*
-
Neoplasm Proteins / immunology
-
Predictive Value of Tests
-
RNA, Messenger / blood
-
RNA, Messenger / immunology
-
RNA, Neoplasm / blood
-
RNA, Neoplasm / immunology
-
Reverse Transcriptase Polymerase Chain Reaction / methods
-
Survival Rate
-
Tumor Cells, Cultured
Substances
-
Antibodies, Monoclonal
-
Antigens, CD
-
IL4 protein, human
-
Immunoglobulins
-
Membrane Glycoproteins
-
Neoplasm Proteins
-
RNA, Messenger
-
RNA, Neoplasm
-
Interleukin-4